F2G’s hopes of getting the first in a brand-new class of antifungals to market have hit a setback courtesy of a complete response letter from the FDA. The regulator was due to make a call on approving ...
Pharmaceutical firms are making progress in addressing the need for new antifungal therapies. F2G says olorofim is part of the first new class of antifungals to be developed in 20 years. F2G’s chief ...
A research team at McMaster University has discovered a new drug class that could someday lead to breakthrough treatments for dangerous fungal infections. The new molecules, dubbed coniotins, were ...
After living with a severe fungal allergy for about 40 years, Jill Fairweather is running out of treatment options. Now 65, Fairweather was diagnosed with aspergillosis, a disease caused by the common ...
RESEARCH TRIANGLE PARK – Durham-based Mycovia Pharmaceuticals has received its first product approval from the U.S. Food and Drug Administration. The FDA granted marketing clearance for VIVJOA ...
A research team at McMaster University has discovered a new drug class that could someday lead to breakthrough treatments for dangerous fungal infections. The new molecules, dubbed coniotins, were ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback